 Indoles
"Indoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
| Descriptor ID |
D007211
|
| MeSH Number(s) |
D03.633.100.473
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Indoles".
Below are MeSH descriptors whose meaning is more specific than "Indoles".
This graph shows the total number of publications written about "Indoles" by people in this website by year, and whether "Indoles" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 3 | 1 | 4 | | 1997 | 2 | 4 | 6 | | 1998 | 0 | 1 | 1 | | 1999 | 1 | 1 | 2 | | 2000 | 1 | 3 | 4 | | 2001 | 2 | 3 | 5 | | 2002 | 1 | 2 | 3 | | 2003 | 0 | 3 | 3 | | 2004 | 1 | 5 | 6 | | 2005 | 1 | 3 | 4 | | 2006 | 2 | 2 | 4 | | 2007 | 5 | 8 | 13 | | 2008 | 4 | 4 | 8 | | 2009 | 3 | 7 | 10 | | 2010 | 3 | 2 | 5 | | 2011 | 3 | 7 | 10 | | 2012 | 5 | 13 | 18 | | 2013 | 8 | 10 | 18 | | 2014 | 13 | 9 | 22 | | 2015 | 12 | 10 | 22 | | 2016 | 7 | 2 | 9 | | 2017 | 9 | 7 | 16 | | 2018 | 8 | 4 | 12 | | 2019 | 6 | 10 | 16 | | 2020 | 2 | 6 | 8 | | 2021 | 8 | 8 | 16 | | 2022 | 0 | 10 | 10 | | 2023 | 2 | 13 | 15 | | 2024 | 12 | 12 | 24 | | 2025 | 17 | 9 | 26 | | 2026 | 9 | 10 | 19 |
To return to the timeline, click here.
Below are the most recent publications written about "Indoles" by people in Profiles.
-
Wang ES, Erba H, Zeidan AM, Roboz GJ, Altman JK, Advani AS, Lin TL, Strickland SA, Juckett MB, Pratz KW, Mangan JK, McMahon CM, Alsfeld LC, Balasubramanian SK, Guru Murthy GS, Rotta M, Palmisiano ND, McCloskey J, Saliba AN, Khawandanah M, Madanat YF, Naqvi K, Qasrawi AH, Schiller GJ, Badar T, Gojo I, Yaghmour G, Osman D, Zhang H, Tian Y, Soifer HS, Riches M, Corum D, Leoni M, Fathi AT, Issa GC. Ziftomenib with venetoclax and azacitidine for relapsed/refractory NPM1-mutated acute myeloid leukemia. Blood. 2026 Oct 01; 148(14):1775-1788.
-
Chmiel JF, McBennett K, Quon BS, Colombo C, De Wachter E, Fajac I, Mondejar-Lopez P, Polineni D, Robinson P, Sutharsan S, Mall MA, McKone EF, Ramsey B, Taylor-Cousar JL, Tullis E, Suresh NE, Zhang Y, Sosnay P, Jennings M, Barry PJ. Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in adolescents and adults with cystic fibrosis and F508del-gating and F508del-residual function genotypes: results from an open-label extension study. Ann Am Thorac Soc. 2026 Sep 01; 23(9):1286-1295.
-
Cooley JC, Penick SK, Wilson JA, Javkhlan N, Foster DG, Edelman BL, Schott CA, Humphries SM, Lynch DA, Schwartz DA, Riches DWH, Redente EF. Nintedanib increases BCL-2 in fibrotic fibroblasts, enhancing ABT-199 apoptosis and fibrosis resolution. Am J Respir Cell Mol Biol. 2026 Aug 01; 74(8):1103-1113.
-
Duncan CL, von Isenburg M, Green A, Ford C, Pucci A, Muther EF, Riekert KA, Bord E, Hoppe JE, Bacon C, Goodman A, Lyons E, Prickett M, Gibson SL, Everhart RS. Caregiver Mental Health and Its Relation to Child and Adolescent Mental and Behavioral Health in the Era of Highly Effective Modulator Therapy for Cystic Fibrosis. Pediatr Pulmonol. 2026 Aug; 61(8):e71794.
-
Phillips WJ, Leong R, Yeung B, Al Lawati A, Camidge DR, Lo B, Wheatley-Price P. The Prognostic Significance of EGFR Adjusted Variant Allele Frequency on First-Line Osimertinib Efficacy in Advanced EGFR-Mutant NSCLC. Curr Oncol. 2026 Jul 23; 33(8).
-
Zemanick ET, Graeber SY, Castellani C, Cutting GR, Fajac I, Konstan MW, Linnemann RW, McKone EF, Metcalf A, Solomon GM, Taylor-Cousar JL, Mayer-Hamblett N, Mall MA. The role of sweat chloride in determining CFTR protein restoration in people with cystic fibrosis. Lancet Respir Med. 2026 Aug; 14(8):704-716.
-
Chalamalla AR, Baker E, Ryan KJ, Dowell A, Natt JR, Zemanick ET, Konstan MW, Mayer-Hamblett N, Acosta EP, Guimbellot JS. Impact of CFTR modulator concentrations on clinical response in cystic fibrosis. Eur Respir J. 2026 Jun; 67(6).
-
Deterding R, Young LR, DeBoer EM, Warburton D, Cunningham S, Schwerk N, Brown KK, Koucký V, Weinman JP, Simmons J, Dumistracel M, Jantzen F, Gahlemann M, Griese M. Continued Nintedanib Treatment in Children and Adolescents With Fibrosing ILDs: Data From InPedILD-ON. Pediatr Pulmonol. 2026 Jun; 61(6):e71707.
-
Muther EF, Gibson SL, Ford C, Duncan C, Riekert KA, Lyons E, Hoppe JE, Prickett M, Isenburg MV, Everhart RS. People with cystic fibrosis' experience of symptom burden while taking elexacaftor/tezacaftor/ivacaftor. Respir Med. 2026 Aug; 259:108908.
-
Dixon BP, Bomback AS, Rich C, Hakimi Z, Huang M, Gordon K, Wojciechowski P, Margas W, Chang R, Duh MS, Caravaca-Fontán F, Fakhouri F. Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment Comparisons. Adv Ther. 2026 Aug; 43(8):3385-3402.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|